UNCLAIMED
Boehringer Ingelheim
Overview
Boehringer Ingelheim is a global company based in the USA, operating within the Biotech and Pharmaceuticals industry since its founding in 1885. With a workforce of approximately 54,500 employees, the company reported revenues of $31,278 million. Boehringer Ingelheim specializes in the development of pharmaceutical products, including those aimed at treating specific conditions in animals. One of the documented areas of expertise is in managing Equine Gastric Ulcer Syndrome (EGUS), as evidenced by their published care plan. This document outlines treatment and management strategies for gastric ulcers in horses, emphasizing the importance of consulting veterinarians for tailored approaches. It details various drug categories for ulcer treatment, including antacids, histamine receptor antagonists, and proton pump inhibitors, specifically mentioning GASTROGARD® (omeprazole) as an FDA-approved treatment. The document also highlights the necessity of combining treatments for optimal healing and provides safety information regarding the use of these medications in horses. Overall, Boehringer Ingelheim's focus on veterinary pharmaceuticals reflects its commitment to animal health.